Raymond James & Associates’s VanEck Biotech ETF BBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $1.11M | Sell |
6,273
-35
| -0.6% | -$6.21K | ﹤0.01% | 2629 |
|
|
2024
Q2 | $1.06M | Sell |
6,308
-125
| -2% | -$20.4K | ﹤0.01% | 2588 |
|
|
2024
Q1 | $1.07M | Sell |
6,433
-800
| -11% | -$132K | ﹤0.01% | 2553 |
|
|
2023
Q4 | $1.2M | Sell |
7,233
-97
| -1% | -$14.9K | ﹤0.01% | 2421 |
|
|
2023
Q3 | $1.14M | Sell |
7,330
-520
| -7% | -$83.1K | ﹤0.01% | 2376 |
|
|
2023
Q2 | $1.22M | Sell |
7,850
-316
| -4% | -$50.5K | ﹤0.01% | 2361 |
|
|
2023
Q1 | $1.32M | Sell |
8,166
-129
| -2% | -$20.9K | ﹤0.01% | 2278 |
|
|
2022
Q4 | $1.33M | Sell |
8,295
-84
| -1% | -$13.3K | ﹤0.01% | 2270 |
|
|
2022
Q3 | $1.18M | Sell |
8,379
-480
| -5% | -$72.6K | ﹤0.01% | 2297 |
|
|
2022
Q2 | $1.29M | Sell |
8,859
-975
| -10% | -$145K | ﹤0.01% | 2281 |
|
|
2022
Q1 | $1.59M | Sell |
9,834
-109
| -1% | -$17.7K | ﹤0.01% | 2288 |
|
|
2021
Q4 | $1.88M | Sell |
9,943
-1,457
| -13% | -$281K | ﹤0.01% | 2218 |
|
|
2021
Q3 | $2.31M | Sell |
11,400
-464
| -4% | -$97.4K | ﹤0.01% | 2007 |
|
|
2021
Q2 | $2.39M | Buy |
11,864
+2,031
| +21% | +$378K | ﹤0.01% | 1974 |
|
|
2021
Q1 | $1.73M | Sell |
9,833
-3,982
| -29% | -$720K | ﹤0.01% | 2124 |
|
|
2020
Q4 | $2.34M | Buy |
13,815
+63
| +0.5% | +$10.4K | ﹤0.01% | 1800 |
|
|
2020
Q3 | $2.23M | Sell |
13,752
-406
| -3% | -$66K | ﹤0.01% | 1689 |
|
|
2020
Q2 | $2.31M | Buy |
14,158
+3,541
| +33% | +$538K | ﹤0.01% | 1652 |
|
|
2020
Q1 | $1.36M | Sell |
10,617
-4,190
| -28% | -$564K | ﹤0.01% | 1792 |
|
|
2019
Q4 | $2.06M | Buy |
14,807
+2,382
| +19% | +$313K | ﹤0.01% | 1810 |
|
|
2019
Q3 | $1.47M | Sell |
12,425
-340
| -3% | -$42.3K | ﹤0.01% | 1946 |
|
|
2019
Q2 | $1.65M | Sell |
12,765
-226
| -2% | -$27.9K | ﹤0.01% | 1905 |
|
|
2019
Q1 | $1.67M | Sell |
12,991
-3,729
| -22% | -$471K | ﹤0.01% | 1879 |
|
|
2018
Q4 | $1.85M | Sell |
16,720
-410
| -2% | -$49.5K | ﹤0.01% | 1709 |
|
|
2018
Q3 | $2.33M | Sell |
17,130
-9
| -0.1% | -$1.17K | ﹤0.01% | 1719 |
|
|
2018
Q2 | $2.06M | Sell |
17,139
-82
| -0.5% | -$9.66K | ﹤0.01% | 1736 |
|
|
2018
Q1 | $2.07M | Sell |
17,221
-1,224
| -7% | -$154K | ﹤0.01% | 1679 |
|
|
2017
Q4 | $2.3M | Sell |
18,445
-365
| -2% | -$46.6K | ﹤0.01% | 1601 |
|
|
2017
Q3 | $2.52M | Buy |
18,810
+12,455
| +196% | +$1.62M | 0.01% | 1482 |
|
|
2017
Q2 | $798K | Buy |
6,355
+400
| +7% | +$48.2K | ﹤0.01% | 2167 |
|
|
2017
Q1 | $709K | Sell |
5,955
-300
| -5% | -$35.1K | ﹤0.01% | 2180 |
|
|
2016
Q4 | $673K | Buy |
6,255
+1,127
| +22% | +$123K | ﹤0.01% | 2152 |
|
|
2016
Q3 | $591K | Buy |
5,128
+290
| +6% | +$33.1K | ﹤0.01% | 2159 |
|
|
2016
Q2 | $495K | Buy |
4,838
+74
| +2% | +$7.89K | ﹤0.01% | 2112 |
|
|
2016
Q1 | $494K | Buy |
+4,764
| New | +$497K | ﹤0.01% | 2049 |
|
Other funds holding BBH
MIM
Raymond James & Associates's BBH Position: Q3 2024 in Review
Raymond James & Associates reduced its VanEck Biotech ETF (BBH) stake by 0.55% in Q3 2024, selling an estimated $6.21K and leaving 6,273 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2629.
Raymond James & Associates first reported a position in BBH in Q1 2016 and has held it in 35 quarters since. The position peaked at $2.52M in Q3 2017. 115 funds tracked by Wall St. Rank hold BBH as of Q3 2024.
- Raymond James & Associates held 6,273 shares of VanEck Biotech ETF worth $1.11M as of Q3 2024.
- Raymond James & Associates sold 35 VanEck Biotech ETF shares in Q3 2024, an estimated $6.21K.
- VanEck Biotech ETF made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2629 holding.
- Raymond James & Associates first reported a position in VanEck Biotech ETF in Q1 2016 and has held it in 35 quarters since.
- Raymond James & Associates's VanEck Biotech ETF position peaked at $2.52M in Q3 2017.
- 115 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.